Goldman Sachs Lowers Estimates on Illumina, But Favors MiSeq Growth Over PGM | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citing a market shift toward the MiSeq desktop sequencer, Goldman Sachs today revised its earnings per share estimates for Illumina.

For 2011, the investment bank maintained EPS estimates at $1.55, but lowered its forecast for 2012 to $2.04 from $2.08, and its estimate for 2013 to $2.64 from $2.70. It also cut its 12-month share price target to $83 from $84.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.